“At the time of database lock (DBL), an insufficient number of overall survival (OS) events (i.e., patient deaths) had been reported to allow calculation of median OS endpoints (i.e., survival remained above 50% at DBL).”
This is why I invested in SPL. Keeping people alive and maintaining quality of life.
Complain all you like about the SP and bad management and poor decisions and missed opportunities, but if you were diagnosed with colorectal or ovarian cancer you would be demanding DEP Irinotecan.
Ann: Positive final DEP irinotecan Phase 2 clinical trial results, page-18
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.0¢ |
Change
0.010(9.09%) |
Mkt cap ! $50.17M | |||
| Open | High | Low | Value | Volume |
| 11.0¢ | 12.0¢ | 11.0¢ | $127.2K | 1.070M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 130918 | 11.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 103000 | 3 |
View Market Depth
| Last trade - 16.10pm 19/11/2024 (20 minute delay) ? |
| SPL (ASX) Chart |